Doliver Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-5,934
Closed -$218K 152
2023
Q2
$218K Hold
5,934
0.07% 153
2023
Q1
$242K Buy
5,934
+1,150
+24% +$49.7K 0.08% 144
2022
Q4
$245K Buy
+4,784
New +$229K 0.08% 133
2022
Q3
Sell
-9,459
Closed -$496K 162
2022
Q2
$496K Buy
+9,459
New +$482K 0.18% 84
2021
Q4
Sell
-16,354
Closed -$703K 183
2021
Q3
$703K Buy
16,354
+1,186
+8% +$52.5K 0.24% 76
2021
Q2
$594K Buy
15,168
+4,275
+39% +$166K 0.2% 81
2021
Q1
$395K Buy
10,893
+800
+8% +$28.4K 0.15% 94
2020
Q4
$372K Buy
10,093
+1,089
+12% +$39.9K 0.16% 90
2020
Q3
$314K Buy
9,004
+440
+5% +$15.4K 0.16% 111
2020
Q2
$266K Buy
8,564
+780
+10% +$26.5K 0.12% 108
2020
Q1
$283K Sell
7,784
-316
-4% -$10.8K 0.14% 87
2019
Q4
$301K Sell
8,100
-597
-7% -$21.3K 0.12% 81
2019
Q3
$301K Buy
8,697
+2,241
+35% +$81.5K 0.12% 79
2019
Q2
$265K Hold
6,456
0.1% 93
2019
Q1
$260K Buy
6,456
+285
+5% +$11.4K 0.11% 75
2018
Q4
$256K Sell
6,171
-108
-2% -$4.48K 0.13% 99
2018
Q3
$263K Buy
+6,279
New +$242K 0.11% 117

Other funds holding PFE

Doliver Advisors's PFE Position: Q3 2023 in Review

Doliver Advisors sold out of Pfizer (PFE) in Q3 2023, closing a stake of 5,934 shares — an estimated $218K sold.

Doliver Advisors first reported a position in PFE in Q3 2018 and held it in 17 quarters. The position peaked at $703K in Q3 2021. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Doliver Advisors reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Doliver Advisors sold 5,934 Pfizer shares in Q3 2023, an estimated $218K.
  • Doliver Advisors first reported a position in Pfizer in Q3 2018 and held it in 17 quarters.
  • Doliver Advisors's Pfizer position peaked at $703K in Q3 2021.
  • 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Doliver Advisors's 13F filing for Q3 2023, filed 10 Oct 2023.